HLA-DM, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-HLA-DM, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | HLA-DM, Human |
| Clone | REA406 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Vio B515 conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Intracellular flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | HLA-DM Antibody, anti-human, Vio® B515, REAfinity™. Clone REA406 recognizes the human HLA-DM antigen, a non-classical MHC class II molecule (MHC II) chaperone that works in lysosomes and endosomes. MHC II molecules are transmembrane glycoproteins which function by binding processed antigenic peptides and presenting them to CD4+ T lymphocytes to initiate or maintain a specific immune response. Constitutive MHC II expression is restricted to professional antigen presenting cells including dendritic cells (DCs), B cells, and macrophages and to the epithelial cells of the thymus. Functional class II expression is highly dependent on the expression of two main chaperones, the invariant chain (Ii) and DM. Newly synthesized class II α- and β-chains form a nonameric complex with three Ii molecules in the endoplasmic reticulum where Ii blocks the peptide-binding groove and guides class II dimers to the endocytic pathway where Ii is proteolytically cleaved leaving the CLIP fragment bound to class II. HLA-DM, an endocytic chaperone, protects empty class II dimers until they bind a peptide capable to confer enough stability to the complex. | Additional information: Clone REA406 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | HLA-DMA, HLA-DMB, DMA, HLADM, RING6, D6S221E, RING7 |
| Gene, Accession # | Gene ID: 3108, 3109 |
| Catalog # | 130-131-216 |
| Price | $158 |
| Order / More Info | HLA-DM, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Oldford, S. A. et al. (2006) Tumor cell expression of HLA-DM associates with a T?1 profile and predicts improved survival in breast carcinoma patients. Int. Immunol. 18 (11): 1591-1602. | van Lith, M. et al. (2010) HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM. J. Biol. Chem. 285 (52): 40800-40808. | Pos, W. et al. (2013) Mechanisms of peptide repertoire selection by HLA-DM. Trends Immunol. 34 (10): 495-501. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies